These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23983935)

  • 21. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
    Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
    Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
    Alphs L; Bossie CA; Sliwa JK; Fu DJ; Ma YW; Hulihan J
    Neuropsychiatr Dis Treat; 2013; 9():341-50. PubMed ID: 23493643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability.
    Gattaz WF; Saracco-Alvarez R; Daltio CS; Van de Bilt MT; Ortegón JJ; Villaseñor-Bayardo SJ; Louzã M; Elkis H; Soares B; Cabrera Jaramillo P; Lawson F; Díaz-Galvis L
    Neuropsychiatr Dis Treat; 2020; 16():2063-2072. PubMed ID: 32982245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia.
    Takahashi N; Takahashi M; Saito T; Iizumi M; Saito Y; Shimizu H; Matsumura T
    Neuropsychiatr Dis Treat; 2013; 9():1889-98. PubMed ID: 24353421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.
    Kim S; Solari H; Weiden PJ; Bishop JR
    Patient Prefer Adherence; 2012; 6():533-45. PubMed ID: 22879739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
    Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
    Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
    Owen RT
    Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
    J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.
    Zhang H; Turkoz I; Zhuo J; Mathews M; Tan W; Feng Y
    Adv Ther; 2017 Nov; 34(11):2503-2517. PubMed ID: 29101715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose.
    Samtani MN; Nuamah I; Gopal S; Remmerie B; Kern Sliwa J; Alphs L
    Neuropsychiatr Dis Treat; 2013; 9():721-30. PubMed ID: 23723704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.